Foley Partner Paul Broude authored an article titled “The IPO Window Is Opening” in the March 2010 issue of MX: Medtech Executive. Broude examines the reasons for a device company to consider an initial public offering for its growth plans, stating that 2010 may bring the promise of IPOs for medical device companies to fund clinical trials, regulatory approvals, and the protection of the company’s intellectual property. He adds that going public enables some medical device and life science companies to continue growing while creating an exit vehicle for management and other shareholders.
Author(s)
Related Insights
January 16, 2026
Energy Current
Fifth Circuit Clears Path for Texas LNG Brownsville Terminal Construction
The Fifth Circuit Court of Appeals on January 14, 2026 overruled the petition of the South Texas Environmental Justice Network (STEJN)…
January 16, 2026
Innovative Technology Insights
Crypto Exits Surge in 2025: Momentum Builds for an Even Bigger 2026
After more than a decade of speculation about when digital‑asset companies would finally break into the public markets at scale, 2025 delivered the long‑awaited breakthrough. Crypto‑related businesses didn’t merely test market appetite—they validated it.
January 15, 2026
The Path & The Practice
Special Episode: Alexis Robertson and Dan Sharpe talk advice to new Big Law associates
In this special edition of The Path & The Practice, Alexis is joined by Dan Sharpe, DEI Manager at Foley & Lardner, for a conversation focused on advice to new associates. Based on their years of legal practice and their experience working in law firm talent development and DEI, they cover a variety of topics including time entry, meeting deadlines, responsiveness, and office presence.